EGFR, an epidermal growth factor receptor, is known to induce proliferation in cancer and is overexpressed in 15% to 30% of patients with BC.[54] It is reported that the drug induces apoptosis in glioblastoma through EGFR-activated Akt/MAPK signaling pathway.[55] Therefore, targeted drugs against EGFR are known to reduce tumor progression and metastasis in patients with BC. Here, AKT1 is linked to cancer.